A	B	C
1	Main
2		Brand	Darzalex
3		Generic	daratumumab
4		Indication	Multiple Myeloma. 68k patients treated in the US
5		MOA	CD38 mab
6		Economics	Genmab. Licensing deal 8/2012.
7		IP
8		Clinical Trials
9			Phase II "GRIFFIN" D-RVd vs. RVd n=207 post-ASCT consolidation MM, NCT02874742
10			sCR 42.4% vs 32%, p=0.068
11			PFS HR=0.45, p=0.0324, median PFS not reached
12			MRD negativity 64% vs 30%